RECURSION PHARMACEUTICALS, INC.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp has disclosed a stake exceeding 5% in Recursion Pharmaceuticals, Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000711). The filing signals that the institutional investor has crossed the key 5% beneficial ownership threshold, making it a notable shareholder in the clinical-stage biotech. Such 13G disclosures are typically passive in nature, indicating the position was not taken with intent to influence control of the company. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further detail in the full filing and any subsequent 13G amendments that reveal changes in State Street's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, Recursion Pharmaceuticals, Inc.